Introduction
Immunoglobulin light chain (AL) amyloidosis has an incidence of 10 per million population per year. 1 Monoclonal Ig light chains produced by a low level of clonal plasma cells in the BM form fibrillar amyloid protein deposits, which accumulate and damage the kidneys, heart, liver, gastrointestinal tract and autonomic nervous system.
Organ failure leads to progressive disability and death. The median survival of untreated patients is 13 months from the time of diagnosis overall and o5 months for patients with cardiomyopathy. High-dose melphalan and auto-SCT (HDM/SCT) can induce complete hematological responses (elimination of the underlying plasma cell dyscrasia and monoclonal gammopathy) and prolong survival. Our experience with more than 300 patients undergoing HDM/SCT 2 suggests that clinical outcomes following HDM/SCT correlate with attaining hematological complete response (HCR) in terms of overall survival (median survival 48 years among patients who achieve HCR compared to 5.2 years for those who do not), organ function (clinical improvement occurs in 2/3 of patients achieving HCR compared with 1/3 of those who do not) and improvement in quality of life. 3 Although HCR is durable in most patients, hematological and clinical relapses do occur in approximately 8% of patients who initially achieve a HCR. Among patients who do not achieve a HCR following HDM/SCT, 30% experience improvement in organ function, but this improvement is typically not durable. Treatment options for relapsed and refractory patients now include proteasome inhibitors and immunomodulators. However, this study was designed before the widespread availability of these agents to explore the utility of a second course of HDM/SCT in patients who relapse after initially responding to a first cycle of HDM/ SCT. Specific objectives of this clinical trial were to determine the feasibility and tolerability of a second course of HDM/ SCT in patients with AL amyloidosis and to determine the rate and durability of response. A secondary objective was to study immune reconstitution after a second SCT.
Patients and methods
This clinical trial was approved by the Institutional Review Board of the Boston University Medical Center in accordance with federal regulations and the declaration of Helsinki.
Eligibility criteria
All patients had a tissue diagnosis of amyloidosis accompanied by an evidence of a clonal plasma cell dyscrasia (abnormal clonal predominance of plasma cells in the BM, and/or presence of a monoclonal gammopathy by immunofixation electrophoresis of serum and/or urine and/or an abnormal serum free light chain concentration and ratio). Patients were o66 years of age, with a Southwest Oncology Group performance status score of 0-2, left ventricular ejection fraction X45% and diffusion lung capacity X50%.
Patients were eligible for a second course of HDM/SCT if they had significant improvement in plasma cell disease and/or organ function after the first course of high-dose melphalan, as defined by any of the following criteria: 4 HCR (absence of monoclonal protein by immunofixation in serum and urine, o5% plasma cells in BM without clonal predominance and normal free light chain ratio if available) or partial response (50% decrease in serum/urine monoclonal protein, or decrease in BM plasmacytosis); 450% reduction in proteinuria with preservation of creatinine clearance; 450% reduction in alkaline phosphatase or X2 cm decrease in liver size by physical exam; improvement in neurological symptoms and exam, confirmed by neurologist; or echocardiographic stabilization of cardiac involvement defined as o2 mm increase in wall thickness. They also had to have had acceptable toxicity during the first course of HDM/SCT, defined as no lifethreatening complications per assessment by their primary hematologist and by the transplant team.
Treatment protocol
Patients who did not have adequate PBSCs cryopreserved from the first SCT within the preceding 10 years, underwent an additional G-CSF mobilization (16 mcg/kg/day for 3 days) of PBSCs and leukapheresis, with a minimum target of 2.5 Â 10 6 CD34 cells/kg. Patients received melphalan at 200 mg/m 2 in two divided doses on day-3 and day-2. Dose reduction to 140 mg/m 2 was allowed at the discretion of the transplant team, generally based on age, performance status and stem cell dose. After stem cell infusion, supportive care included G-CSF, antiemetics, mouth care and prophylactic antimicrobials (quinolone, fluconazole and acyclovir).
Toxicity and response criteria
The National Cancer Institute (Bethesda, MD, USA) Common Terminology Criteria for Adverse Events v3.0 was used to grade adverse events. A HCR was defined as absence of monoclonal protein in serum and urine by immunofixation electrophoresis, a normal BM biopsy with o5% plasma cells and no clonal predominance by immunohistochemistry and a normal serum Ig free light chain ratio (after the latter test became available during the course of this study). A hematological partial response was defined as 50% reduction of serum monoclonal protein, serum free light chain, or light chain in the urine. Clinical/ organ responses were defined according to the consensus report from the 10th International Symposium on Amyloid and Amyloidosis. 4 Patients were assessed for hematological and clinical responses at 6 months, 12 months and annually thereafter. Studies of immune reconstitution consist of Ig levels and T/B/NK cell subsets by flow cytometry and were obtained at day 14, 12 months and annually thereafter.
Statistical analysis
The feasibility of second PBSC mobilization was assessed by the percentage of patients for whom an adequate second stem cell autograft was obtainable. Days to neutrophil and platelet engraftment were compared for both SCTs using a paired t-test. The proportion of patients who experienced grade IV non-hematological toxicities for the first HDM/ SCT was compared with that for the second HDM/SCT by the McNemar's test for paired data.
Results

Patient characteristics
From January 2002 to June 2008, 11 patients with relapsed AL amyloidosis after SCT were enrolled on this protocol (see Table 1 ). The median age was 55 (range 39-62 years), with seven men and four women. Nine patients (82%) had a lambda and two patients (18%) had a kappa-clonal plasma cell dyscrasia. Organ involvement consisted of renal (91%), cardiac (73%), neurological (45%) and hepatic or gastrointestinal disease (45%), with more than one organ system involvement in all but one patient. Response after the first course of HDM/SCT was a HCR in four patients, partial response in five patients and not available for two patients. The median time interval between the two transplants was 34 months (range 12-63 months).
Second PBSC mobilization and hematopoietic engraftment kinetics . The mean cell dose infused was 6.1 million (range 3.4-10.5 million) CD34 cells/kg. Engraftment occurred at a median of 10 days for neutrophils and 12 days for platelets. This engraftment timing is similar to that following the initial transplant (10 days for neutrophils, 13 days for platelets; data from nine patients).
Treatment-related toxicity
There was no treatment-related mortality, defined as death occurring within 100 days of HDM/SCT. Grade IV nonhematological toxicities occurred in 22% (2/9) patients Second stem cell transplant relapse AL amyloidosis K Quillen et al after the first HDM/SCT and in 55% (6/11) patients after the second HDM/SCT (P ¼ 0.41, see Table 2 ). The latter included three episodes of sepsis/febrile neutropenia and two cases of acute renal failure (ARF) requiring dialysis. The two patients who experienced ARF had impaired creatinine clearance before transplant: one of them remained dialysis dependent post transplant until he expired at 14 months; the other received a kidney transplant 3 years after second HDM/SCT. Two patients experienced high fever (temperature 439 1C) within 12-24 h of receiving HDM, with negative blood cultures and normal to elevated neutrophil counts. We have previously reported on this so-called 'melphalan recall' reaction. 5 
Hematological response and survival
In all, 4 of the 11 patients (36%) achieved HCR at 1 year. Two of these patients subsequently relapsed (at 2 and 3 years after second HDM/SCT) and were treated with lenalidomide. The other two patients continue in HCR at 3 and 6 years after second HDM/SCT. Four patients (36%) achieved a partial hematological response at 1 year. Of these, three have progressed at 3 years after second HDM/ SCT and one is receiving lenalidomide. Three patients died of progressive disease 1-2 years after the second HDM/ SCT. Median follow-up for survivors is 3 years. Median survival has not yet been reached. (see Figure 1 )
Post transplant infections (beyond day þ 100) and immune reconstitution One patient had herpes zoster at 1 and 6 months after second SCT. In all, 6 of the 11 patients had annual followup at our institution for evaluation of immune reconstitution. In all, 83% (five out of six) of these evaluable patients had normal Ig levels and T cell and NK cell numbers at 1 year follow-up, which were sustained thereafter. Only one patient had mild T-cell lymphopenia, which has persisted without any opportunistic infections; he achieved HCR at 1 year, but relapsed at 3 years after second SCT.
Discussion
HDM/SCT is an option for just over half of the patients referred to our center with AL amyloidosis. 2 HDM/SCT produces a HCR in about 40% of the patients and improved quality of life. 3 The median survival is 5.2 years for patients who do not achieve HCR and more than 8 years in patients who do achieve HCR. The relapse rate after achieving HCR is approximately 8%. 2 In a study of patients who did not achieve initial HCR after HDM/SCT, 31% achieved HCR after a subsequent 'tandem' cycle of HDM/SCT, performed within 6-12 months of the first cycle. 6 This approach has been shown to confer a survival benefit for patients with multiple myeloma. [7] [8] [9] Among other patients who achieve a partial response after initial HDM/ SCT, 30%, nevertheless, may experience improved organ function, 2 but subsequently require additional therapy for progressive disease. The current study shows that a second cycle of HDM/SCT for relapsed disease produces a HCR in more than one-third of patients assessed at 1 year, with a durable remission achievable in some of these responders.
Therapeutic options in AL amyloidosis have been extended in the last several years. 10 However, it has been appreciated that AL amyloidosis patients are at a higher risk of toxicity from underlying renal, cardiac, and neurological impairment. Thalidomide was studied as a single agent, 11 then combined with dexamethasone. The combination was active, but poorly tolerated. 12 In a Phase 2 study of lenalidomide and dexamethasone in 34 patients with AL amyloidosis, of whom 19 (56%) had received previous HDM/SCT, HCR was achieved in 29% of patients. 13 Median time to hematological response was six cycles. Grade 3 or 4 toxicities included myelosuppression (35%), fatigue (35%) and skin rash (18%). In a Phase 1 dose-escalation study of bortezomib in 31 patients, of Table 2 Grade IV non-hematologic treatment-related adverse events Second stem cell transplant relapse AL amyloidosis K Quillen et al whom 13 (42%) had undergone previous HDM/SCT, onceweekly dosing at 1.6 mg/m 2 (4 weeks out of 5-week cycle) and twice-weekly dosing at 1.3 mg/m 2 produced HCR in 5/12 (42%) patients who received these doses.
14 Overall HCR was 20%, and median time to first response was 1.2 months. Common toxicities were gastrointestinal events, fatigue and neurological (dizziness and paresthesia). A similar HCR of 20% was observed in a retrospective analysis of twice-weekly bortezomib in 94 patients, of whom 11 (12%) had had previous HDM/SCT. 15 This study of second HDM/SCT was designed before the availability of the newer agents. Second stem cell mobilization after a previous cycle of HDM/SCT had not been well studied. 16 The five patients in our series who underwent second mobilization with G-CSF had a median interval of 39 months (range 16-63 months) between HDM cycles and all successfully re-mobilized with an adequate CD34 þ cell yield and engraftment kinetics after the second cycle of HDM. Immune reconstitution appears adequate in terms of T cell, B cell, and NK cell numbers and the absence of opportunistic infections.
In our previous experience with tandem transplantation in AL amyloidosis, treatment-related mortality was 6% (1/17) after the second cycle of HDM/SCT and the incidence of grade IV non-hematological toxicities was 24% (4/17). Both these outcomes were comparable to those for the first cycle of HDM/SCT (8 and 25% respectively). 6 In the current smaller series of delayed second transplant for relapse, the second cycle of HDM was associated with a much higher incidence (55%) of grade IV non-hematological toxicities, although there was no treatment-related mortality. Two patients experienced a 'melphalan recall' reaction characterized by high fever, neutrophilic leukocytosis with bandemia and negative blood cultures within 12-24 h of receiving HDM. We postulate that this is a cytokine-mediated phenomenon and have observed it in nine other patients undergoing tandem transplant for AL amyloidosis. 5 ARF necessitating dialysis occurred in two patients. One patient remained dialysis dependent and died at 14 months from progressive disease. The other patient achieved HCR and received a living donor kidney transplant 33 months after the second HDM/SCT. She remains in HCR 6 years after the second SCT. Retrospective review of renal toxicity of HDM/SCT in AL amyloidosis at our institution showed that 21% (37/173) of patients developed ARF, but dialysis was required in only 5% (9/173). Baseline clinical variables that were independent predictors of transplant-associated ARF included creatinine clearance, proteinuria and cardiac involvement. Treatment-related variables associated with ARF included melphalan dose and bacteremia. 17 The two patients in the current series who developed ARF both had nephrotic range proteinuria and impaired creatinine clearance before second HDM/SCT.
In conclusion, a second cycle of HDM/SCT is a reasonable option in patients who relapse after a first transplant, with a HCR rate that is comparable to that of lenalidomide or bortezomib, with morbidity but no mortality at our center. These data indicate that second HDM/SCT is possible. In the future, second HDM/SCT will most likely be reserved for progressive disease after a trial of a proteasome inhibitor and/or an immunomodulator, or for patients intolerant to these agents.
